Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 50: 228-231, 2004; 10.1373/clinchem.2003.021022
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schmid, C.
Right arrow Articles by Wiesli, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schmid, C.
Right arrow Articles by Wiesli, P.
Related Collections
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2004;50:228-231.)
© 2004 American Association for Clinical Chemistry, Inc.

Technical Briefs

Effect of Thyroxine Replacement on Creatinine, Insulin-Like Growth Factor 1, Acid-Labile Subunit, and Vascular Endothelial Growth Factor

Christoph Schmid1, Michael Brändle1, Cornelia Zwimpfer1, Jürgen Zapf1 and Peter Wieslia,1

1 Department of Internal Medicine, Division of Endocrinology and Diabetes, University Hospital of Zurich, CH-8091 Zurich, Switzerland

aauthor for correspondence: fax 41-1-255-4447, e-mail peter.wiesli@dim.usz.ch

The first 20% of the full text of this article appears below.

Hypothyroidism is associated with endothelial dysfunction, arterial hypertension, and impaired kidney function (1)(2)(3). An increased serum creatinine and decreased glomerular filtration rate and renal blood flow have been described (2)(4)(5). These deleterious consequences may result from several mechanisms, including direct and indirect effects of thyroid hormones on blood vessels. Insulin-like growth factor 1 (IGF-1) and vascular endothelial growth factor (VEGF), growth factors with both local and systemic effects, may be involved as potential mediators. Hypothyroidism causes low concentrations of IGF-1, which can be normalized by thyroxine replacement therapy (6). IGF-1 is known to increase forearm blood flow and creatinine clearance in humans (7)(8)(9). VEGF increases endothelial nitric oxide synthase activity, contributing to the relaxing capacity of the renal vasculature (10)(11)(12)(13). Thus, both IGF-1 and VEGF may improve endothelial function and renal blood flow.

The purpose of this study was to test the effect of thyroxine therapy on serum creatinine, IGF-1, and VEGF in hypothyroid patients. Patients with newly diagnosed primary hypothyroidism who had been referred to the Division of Endocrinology and Diabetes at the University Hospital in Zurich between February 1998 and July 2002 were included in this prospective case series. Oral informed consent was obtained from all patients. Patients with neoplastic disease, secondary hypothyroidism, and thyroid cancer were excluded from the study because VEGF is often increased in patients with tumors, including tumors of the pituitary gland and the thyroid (14)(15).

All laboratory values were measured . . . [Full Text of this Article]




The following articles in journals at HighWire Press have cited this article:


Home page
 EndocrinologyHome page
Y. Debaveye, B. Ellger, L. Mebis, E. Van Herck, W. Coopmans, V. Darras, and G. Van den Berghe
Tissue Deiodinase Activity during Prolonged Critical Illness: Effects of Exogenous Thyrotropin-Releasing Hormone and Its Combination with Growth Hormone-Releasing Peptide-2
Endocrinology, December 1, 2005; 146(12): 5604 - 5611.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Association for Clinical Chemistry.